WinstonWınston
Medra Corporation logo

Medra Corporation

MDRA
34
Chemicals - Specialty · Basic Materials
Price
$0.02
+0.00 (+0.00%)
Market Cap
$686,926
Winston Score
34
Winston is serious
Below-average fundamentals — multiple weak pillars.

Share count rising — dilution

+118.3% over 2y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 15K (1999) → 32K (2001)

Medra Corporation is a small specialty chemicals company. It produces chemical products sold to industrial and commercial customers. The specialty chemicals industry serves a wide range of end markets, including manufacturing, agriculture, and consumer goods.

Medra generates revenue by selling its chemical products directly to business customers. The company appears to operate at a very small scale, with a market cap near zero and a gross margin of roughly 9%, which is thin for the specialty chemicals sector. The operating margin figure in available data appears anomalous and likely reflects unusual one-time accounting items rather than true business performance. Medra faces the typical risks of a micro-cap chemicals company, including raw material cost pressure, limited pricing power, and the challenge of competing against much larger, better-resourced chemical producers — all of which make sustained profitability difficult to achieve.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-16.9% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+37.5% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$2M/ year

Rising (+39% vs prior year)

217.2% of revenue

72.4x the sector average (3%)

Investing heavily in future products and technology

Insider Activity

100.0%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~0 months

$39,151 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Heavy R&D investment

Medra Corporation is putting 217% of revenue into R&D and that number is rising. That's 72.4x the sector average.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
-126.0%
Thin — -126.0% gross margin
Operating Margin
1004.2%
Excellent — 1004.2% operating margin
ROCE
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+40.0%
Fast-growing sales (40.0% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
0/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
-417.9%
Burning cash (-417.9%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
N/A
Data not available
Interest Cover
100.00x
Comfortably covers interest (100.0x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial